Diabetes medication

Latest Data From SURPASS Trials Demonstrate Tirzepatide Provided Meaningful Blood Sugar Reductions And Weight Loss

Retrieved on: 
Tuesday, June 29, 2021
Branches of biology, Peptide hormones, Clinical medicine, Medicine, Recombinant proteins, Diabetes, Insulin, Semaglutide, Type 2 diabetes, Diabetes medication, Insulin analog

Tirzepatide is under development and in phase three of clinical trials for the treatment of type 2 diabetes.

Key Points: 
  • Tirzepatide is under development and in phase three of clinical trials for the treatment of type 2 diabetes.
  • In SURPASS-2, all three tirzepatide doses delivered superior A1C and body weight reductions from baseline compared to semaglutide.
  • In SURPASS-3, all three tirzepatide doses delivered superior A1C and body weight reductions from baseline compared to titrated insulin degludec.
  • In SURPASS-5, all three tirzepatide doses delivered superior A1C reductions and weight reductions compared to placebo both added to titrated insulin glargine.

Liraglutide And Insulin More Effective In Maintaining Average Blood Glucose Levels Than Other Common Diabetes Drugs

Retrieved on: 
Monday, June 28, 2021
Diabetes, Clinical medicine, Organ systems, Medicine, Type 2 diabetes, Metformin, Liraglutide, Insulin, Blood sugar level, Diabetes management, Diabetes medication

It was designed to compare the effectiveness of glucose-lowering medications in maintaining average blood glucose levels in the target range that has been identified to reduce the risk of long-term complications.

Key Points: 
  • It was designed to compare the effectiveness of glucose-lowering medications in maintaining average blood glucose levels in the target range that has been identified to reduce the risk of long-term complications.
  • Medications in addition to metformin, which is recommended by the ADA for initial use to treat type 2 diabetes, are often needed to treat type 2 diabetes to help lowerA1C levels.
  • The study enrolled more than 5,000 patients with type 2 diabetes with an average age of 57 years and an average duration of diabetes of four years.
  • Results of GRADE demonstrated that liraglutide and insulin were the most effective of the four medications in keeping A1C levels less than 7%.

REMD Biotherapeutics Announces Positive Top-Line Results in a Phase 2 Program of Lead Product Candidate Volagidemab in Patients with Type 1 Diabetes

Retrieved on: 
Monday, June 28, 2021
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical trials, Diabetes, Clinical medicine, Organ systems, Branches of biology, Insulin, Type 1 diabetes, Glycated hemoglobin, Diabetes management, Diabetes medication, Type 1 Diabetes, REMD Biotherapeutics, TYPE 1 DIABETES, REMD BIOTHERAPEUTICS

Trial 2 results showed a statistically significant and clinically meaningful decrease in hemoglobin A1C and daily insulin use.

Key Points: 
  • Trial 2 results showed a statistically significant and clinically meaningful decrease in hemoglobin A1C and daily insulin use.
  • Type 1 diabetes typically results from the autoimmune destruction of the insulin-producing -cells in the pancreas.
  • Presently, the primary therapy for type 1 diabetes is insulin; there is no cure and no means of prevention.
  • In addition, fewer than one-third of people with type 1 diabetes in the U.S. consistently achieve target blood-glucose control.

Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX

Retrieved on: 
Friday, June 25, 2021
Branches of biology, Hormones, Organ systems, Obesity, CYP17A1 inhibitors, Thiazolidinediones, Connective tissue, Pioglitazone, Pyridines, Diabetes medication, Insulin, Thiazolidinedione

The posters are available starting at 11:30am ET on June 25, 2021 and will be posted to the companys website.

Key Points: 
  • The posters are available starting at 11:30am ET on June 25, 2021 and will be posted to the companys website.
  • These improvements, including a clinically meaningful and statistically significant reduction in HbA1c, were seen on top of concomitant anti-diabetic medications.
  • These secondary analyses highlight the potential of FGFR1c-mediated reprogramming of adipose metabolism in NASH patients to improve liver health.
  • Insulin-sensitizing therapeutics acting predominantly on adipose tissue, such as pioglitazone, have historically been associated with weight gain.